Provided by Tiger Trade Technology Pte. Ltd.

WUXI XDC

62.800
-1.650-2.56%
Volume:6.45M
Turnover:404.43M
Market Cap:79.00B
PE:62.68
High:64.400
Open:64.300
Low:62.000
Close:64.450
52wk High:85.500
52wk Low:24.700
Shares:1.26B
HK Float Shares:1.26B
Volume Ratio:1.91
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.002
ROE:19.76%
ROA:9.04%
PB:9.46
PE(LYR):62.68
PS:13.83

Loading ...

WuXi XDC Cayman (SEHK:2268) Margin Guidance Rises on 2025 Outlook – What Is Driving Profitability?

Simply Wall St.
·
Jan 23

WuXi XDC (02268) Issues 2.7517 Million Shares Under Share Scheme

Stock News
·
Jan 22

Daiwa: Assigns "Buy" Rating to WUXI BIO (02269), Expects BIODLINK-B (01875) to Maintain Listing Status

Stock News
·
Jan 19

WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit

MT Newswires Live
·
Jan 15

Zhutong Hong Kong Stock Morning Briefing | Ministry of Finance Holds Meeting on Fiscal-Financial Synergy to Boost Domestic Demand; White House Announces 25% Tariff Hike on Specific Semiconductors

Stock News
·
Jan 15

Strong Earnings and Acquisition of TOT Biopharm Bolster WUXI XDC's (02268) Position in ADC CDMO Market

Stock News
·
Jan 14

Hong Kong Stock Announcement Highlights | BIODLINK-B Receives 99% Premium Cash Offer from WUXI XDC, Resumes Trading on January 15

Stock News
·
Jan 14

BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares

Reuters
·
Jan 14

BIODLINK-B (01875) Receives Cash Offer from WUXI XDC (02268) at Approximately 99% Premium, Trading Resumes January 15

Stock News
·
Jan 14

WUXI XDC (02268) Issues Profit Alert, Anticipates 2025 Net Profit to Surge Over 38%

Stock News
·
Jan 14

WuXi XDC Cayman Launches Voluntary Cash Offer for All Outstanding Shares and Options

Reuters
·
Jan 14

WuXi XDC Cayman Inc - FY Revenue Expected to Increase by More Than 45%

THOMSON REUTERS
·
Jan 14

WuXi XDC Cayman Inc Sees FY Net Profit to Increase by More Than 38%

THOMSON REUTERS
·
Jan 14

WuXi XDC Cayman Expects Net Profit to Rise Over 38% for 2025

Reuters
·
Jan 14

Gelonghui's 2026 "Bet on China" Top 10 Core Assets List, Officially Revealed!

Deep News
·
Jan 01

This WuXi XDC Cayman Insider Reduced Their Stake By 100%

Simply Wall St.
·
Dec 31, 2025

Akari Therapeutics Partners with WuXi XDC to Advance ADC Candidate Toward Clinical Trials

Reuters
·
Dec 30, 2025

WuXi XDC Selected to Manufacture Akari Therapeutics' AKTX-101 for Phase 1 Clinical Trial

Reuters
·
Dec 23, 2025

Akari Therapeutics Initiates Gmp Manufacturing of Aktx-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

THOMSON REUTERS
·
Dec 23, 2025

CMB International: 2025 Medical Insurance Catalog Continues Support for Innovation, Expects CXO Sector Recovery in H2

Stock News
·
Dec 09, 2025